Post-operative survival of patients with lung cancer
Mené sur 2 312 patients atteints d'un cancer du poumon non à petites cellules surexprimant MAGE-A3, cet essai randomisé international de phase III évalue l'efficacité, du point de vue de la survie sans maladie, et la toxicité d'une immunothérapie en traitement adjuvant
Surgery remains the best chance of cure for lung cancer. However, only about 25% of all patients diagnosed with lung cancer can be operated on because of the extent of disease or comorbidities often linked to tobacco that preclude any surgery. Survival is highly dependent on the pathological stage. Only neoadjuvant and adjuvant chemotherapy results in improved survival (from roughly 40–45% at 5 years).
The Lancet Oncology , commentaire, 2015